RedCord in Neurogenic Bowel Dysfunction in Multiple Sclerosis
Effectiveness of Treatment With RedCord in Neurogenic Bowel Dysfunction in People With Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- Redcord
Compared with
- Control (Standard treatment)
What it measured
Main measures
Neurogenic Bowel Dysfunction score (NBDS)
baseline, 6, 12 and 24 weeks
Bladder, bowel and sexual function
Other measures (1)
Electromyography: Root mean square
baseline, 6, 12 and 24 weeks
Who could take part
MS (type not specified) · 30 to 60
Show the full criteria
Inclusion criteria
* People diagnosed with Multiple Sclerosis according to McDonald's criteria. * EDSS less than 6 points. * Willingness to participate.
Exclusion criteria
* People with cognitive impairment, which makes it difficult to understand the questionnaires properly. * Pregnant women. * Severe psychological or psychiatric pathology diagnosed.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The study aims to evaluate the effectiveness of Redcord treatment for neurogenic bowel dysfunction in patients with multiple sclerosis. The main objectives are: * Assess the impact of Redcord on bowel function and quality of life in multiple sclerosis patients. * Compare the outcomes of Redcord treatment with standard care practices. Participants will undergo Redcord therapy sessions and their bowel function will be monitored and compared to a control group receiving standard care. The study will measure improvements in bowel control, frequency, and overall patient satisfaction.
Loading reviews and guidelines…
History
Started
Sept 2025
Main results due
Sept 2026
Finished
Dec 2026